Johnson & Johnson Employee-related Liabilities
Johnson & Johnson (JNJ) had Employee-related Liabilities of $6.66 billion as of 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Liabilities
us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent · last filed 2026-07-23
- 2026-06-28: Employee-related Liabilities $6.66B.
- 2026-03-29: Employee-related Liabilities $6.76B.
- 2025-12-28: Employee-related Liabilities $6.96B.
- 2025-09-28: Employee-related Liabilities $6.93B.
| Period end | Employee-related Liabilities | Employee-related Liabilities as first filed |
|---|---|---|
| 2026-06-28 | $6.66B 10-Q · filed 2026-07-23 | |
| 2026-03-29 | $6.76B 10-Q · filed 2026-04-22 | |
| 2025-12-28 | $6.96B 10-Q · filed 2026-07-23 | |
| 2025-09-28 | $6.93B 10-Q · filed 2025-10-22 | |
| 2025-06-29 | $7.02B 10-Q · filed 2025-07-24 | |
| 2025-03-30 | $7.05B 10-Q · filed 2025-04-23 | |
| 2024-12-29 | $7.25B 10-Q · filed 2025-10-22 | |
| 2024-09-29 | $6.85B 10-Q · filed 2024-10-23 | |
| 2024-06-30 | $6.92B 10-Q · filed 2024-07-25 | |
| 2024-03-31 | $7.02B 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $7.15B 10-Q · filed 2024-10-23 | |
| 2023-10-01 | $5.69B 10-Q · filed 2023-10-27 | |
| 2023-07-02 | $6.46B 10-Q · filed 2023-07-31 | |
| 2023-04-02 | $6.67B 10-Q · filed 2023-04-28 | |
| 2023-01-01 | $6.54B 10-Q · filed 2023-10-27 | $6.77B 10-Q · filed 2023-04-28 |
| 2022-10-02 | $8.35B 10-Q · filed 2022-10-27 | |
| 2022-07-03 | $8.55B 10-Q · filed 2022-07-29 | |
| 2022-04-03 | $8.74B 10-Q · filed 2022-04-29 | |
| 2022-01-02 | $8.90B 10-Q · filed 2022-10-27 | |
| 2021-10-03 | $10.17B 10-Q · filed 2021-10-29 | |
| 2021-07-04 | $10.37B 10-Q · filed 2021-07-29 | |
| 2021-04-04 | $10.51B 10-Q · filed 2021-04-30 | |
| 2021-01-03 | $10.77B 10-Q · filed 2021-10-29 | |
| 2020-09-27 | $10.18B 10-Q · filed 2020-10-23 | |
| 2020-06-28 | $10.41B 10-Q · filed 2020-07-24 | |
| 2020-03-29 | $10.53B 10-Q · filed 2020-04-29 | |
| 2019-12-29 | $10.66B 10-Q · filed 2020-10-23 | |
| 2019-09-29 | $9.83B 10-Q · filed 2019-10-28 | |
| 2019-06-30 | $9.91B 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $9.90B 10-Q · filed 2019-05-01 | |
| 2018-12-30 | $9.95B 10-Q · filed 2019-10-28 | |
| 2018-09-30 | $9.37B 10-Q · filed 2018-10-31 | |
| 2018-07-01 | $9.99B 10-Q · filed 2018-08-02 | |
| 2018-04-01 | $10.07B 10-Q · filed 2018-05-01 | |
| 2017-12-31 | $10.07B 10-Q · filed 2018-10-31 | |
| 2017-10-01 | $9.69B 10-Q · filed 2017-11-02 | |
| 2017-07-02 | $9.69B 10-Q · filed 2017-08-03 | |
| 2017-01-01 | $9.62B 10-Q · filed 2017-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |